These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 24174400)

  • 41. Conformational implications of an inversed pH-dependent antibody aggregation.
    Perico N; Purtell J; Dillon TM; Ricci MS
    J Pharm Sci; 2009 Sep; 98(9):3031-42. PubMed ID: 18803243
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Peptide Optimization at the Drug Discovery-Development Interface: Tailoring of Physicochemical Properties Toward Specific Formulation Requirements.
    Evers A; Pfeiffer-Marek S; Bossart M; Heubel C; Stock U; Tiwari G; Gebauer B; Elshorst B; Pfenninger A; Lukasczyk U; Hessler G; Kamm W; Wagner M
    J Pharm Sci; 2019 Apr; 108(4):1404-1414. PubMed ID: 30528197
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Studying Excipient Modulated Physical Stability and Viscosity of Monoclonal Antibody Formulations Using Small-Angle Scattering.
    Xu AY; Castellanos MM; Mattison K; Krueger S; Curtis JE
    Mol Pharm; 2019 Oct; 16(10):4319-4338. PubMed ID: 31487466
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Characterizing and Minimizing Aggregation and Particle Formation of Three Recombinant Fusion-Protein Bulk Antigens for Use in a Candidate Trivalent Rotavirus Vaccine.
    Agarwal S; Sahni N; Hickey JM; Robertson GA; Sitrin R; Cryz S; Joshi SB; Volkin DB
    J Pharm Sci; 2020 Jan; 109(1):394-406. PubMed ID: 31400346
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Advanced protein formulations.
    Wang W
    Protein Sci; 2015 Jul; 24(7):1031-9. PubMed ID: 25858529
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Rapid sample-saving biophysical characterisation and long-term storage stability of liquid interferon alpha2a formulations: Is there a correlation?
    Svilenov H; Winter G
    Int J Pharm; 2019 May; 562():42-50. PubMed ID: 30878589
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Development of stable lyophilized protein drug products.
    Remmele RL; Krishnan S; Callahan WJ
    Curr Pharm Biotechnol; 2012 Mar; 13(3):471-96. PubMed ID: 22283723
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Probing Protein Conformation Destabilization in Sterile Liquid Formulations through the Formation of 3,4-Dihydroxyphenylalanine.
    Mozziconacci O; Subelzu N; Schöneich C; Liu Y; Abend A; Wuelfing WP
    Mol Pharm; 2020 Oct; 17(10):3783-3793. PubMed ID: 32910663
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pulse Proteolysis: An Orthogonal Tool for Protein Formulation Screening.
    Iyer LK; Phanse R; Xu M; Lan W; Krause ME; Bolgar M; Hart S
    J Pharm Sci; 2019 Feb; 108(2):842-850. PubMed ID: 30257193
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Physical stability of albinterferon-α(2b) in aqueous solution: effects of conformational stability and colloidal stability on aggregation.
    Chou DK; Krishnamurthy R; Manning MC; Randolph TW; Carpenter JF
    J Pharm Sci; 2012 Aug; 101(8):2702-19. PubMed ID: 22674119
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Binding of excipients is a poor predictor for aggregation kinetics of biopharmaceutical proteins.
    Zalar M; Svilenov HL; Golovanov AP
    Eur J Pharm Biopharm; 2020 Jun; 151():127-136. PubMed ID: 32283214
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Formulation development of therapeutic monoclonal antibodies using high-throughput fluorescence and static light scattering techniques: role of conformational and colloidal stability.
    Goldberg DS; Bishop SM; Shah AU; Sathish HA
    J Pharm Sci; 2011 Apr; 100(4):1306-15. PubMed ID: 20960568
    [TBL] [Abstract][Full Text] [Related]  

  • 53. High-throughput assessment of antigen conformational stability by ultraviolet absorption spectroscopy and its application to excipient screening.
    Dasnoy S; Le Bras V; Préat V; Lemoine D
    Biotechnol Bioeng; 2012 Feb; 109(2):502-16. PubMed ID: 21928339
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Advancements in high throughput biophysical technologies: applications for characterization and screening during early formulation development of monoclonal antibodies.
    Samra HS; He F
    Mol Pharm; 2012 Apr; 9(4):696-707. PubMed ID: 22263524
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Conformational analysis of protein secondary structure during spray-drying of antibody/mannitol formulations.
    Schüle S; Friess W; Bechtold-Peters K; Garidel P
    Eur J Pharm Biopharm; 2007 Jan; 65(1):1-9. PubMed ID: 17034996
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Local dynamics and their alteration by excipients modulate the global conformational stability of an lgG1 monoclonal antibody.
    Thakkar SV; Kim JH; Samra HS; Sathish HA; Bishop SM; Joshi SB; Volkin DB; Middaugh CR
    J Pharm Sci; 2012 Dec; 101(12):4444-57. PubMed ID: 23060088
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Lyophilization and development of solid protein pharmaceuticals.
    Wang W
    Int J Pharm; 2000 Aug; 203(1-2):1-60. PubMed ID: 10967427
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Temperature-ramped studies on the aggregation, unfolding, and interaction of a therapeutic monoclonal antibody.
    Menzen T; Friess W
    J Pharm Sci; 2014 Feb; 103(2):445-55. PubMed ID: 24382634
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Computational Design To Reduce Conformational Flexibility and Aggregation Rates of an Antibody Fab Fragment.
    Zhang C; Samad M; Yu H; Chakroun N; Hilton D; Dalby PA
    Mol Pharm; 2018 Aug; 15(8):3079-3092. PubMed ID: 29897777
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Trends on Analytical Characterization of Polysorbates and Their Degradation Products in Biopharmaceutical Formulations.
    Martos A; Koch W; Jiskoot W; Wuchner K; Winter G; Friess W; Hawe A
    J Pharm Sci; 2017 Jul; 106(7):1722-1735. PubMed ID: 28302541
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.